Christian Hlscher

List of Publications by Year in Descending Order

197 papers	11,847 citations	61 h-index	103 g-index
211 ext. papers	13,785 ext. citations	4.7 avg, IF	7.14 L-index

#	Paper	IF	Citations
197	(D-Ser2) oxyntomodulin recovers hippocampal synaptic structure and theta rhythm in Alzheimer's disease transgenic mice.. *Neural Regeneration Research*, **2022**, 17, 2072-2078	4.5	0
196	Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson's Disease Mouse Model.. *Frontiers in Neuroscience*, **2022**, 16, 814430	5.1	2
195	Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research.. *Frontiers in Neurology*, **2022**, 13, 844697	4.1	2
194	Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and -synuclein accumulation in the colon of two Parkinson's disease mouse models.. *European Journal of Pharmacology*, **2022**, 175029	5.3	1
193	033 GLP-1RAs reduce stroke incidence in patients with type 2 diabetes mellitus: a meta-analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**, 93, A111.1-A111	5.5	
192	DAla2-GIP-GLU-PAL Protects Against Cognitive Deficits and Pathology in APP/PS1 Mice by Inhibiting Neuroinflammation and Upregulating cAMP/PKA/CREB Signaling Pathways. *Journal of Alzheimer's Disease*, **2021**, 80, 695-713	4.3	3
191	Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model. *Journal of Parkinson's Disease*, **2021**, 11, 529-543	5.3	2
190	Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. *British Journal of Pharmacology*, **2021**,	8.6	11
189	The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-B inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01. *Brain and Behavior*, **2021**, 11, e2231	3.4	5
188	A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model. *Drug Research*, **2021**, 71, 43-50	1.8	1
187	Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 14-30	7.3	10
186	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. *Alzheimer's Research and Therapy*, **2021**, 13, 47	9	14
185	Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis. *Journal of Natural Medicines*, **2021**, 75, 540-552	2.3	11
184	The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1 and TDP-43 transgenic mouse models of ALS. *Scientific Reports*, **2021**, 11, 17027	4.9	0
183	A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2021**, 83, 799-818	4.3	2
182	Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. *Neural Regeneration Research*, **2021**, 16, 1660-1670	4.5	7
181	The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 333-343	4.5	6

180	Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease. *Frontiers in Neuroscience*, **2020**, 14, 614828	5.1	7
179	The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties in the APP/PS1 mouse model of Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e039220	1.2	
178	Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α. *Biomedicine and Pharmacotherapy*, **2020**, 127, 110155	7.5	12
177	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. *Expert Opinion on Investigational Drugs*, **2020**, 29, 333-348	5.9	44
176	Driving GABAergic neurons optogenetically improves learning, reduces amyloid load and enhances autophagy in a mouse model of Alzheimer's disease. *Biochemical and Biophysical Research Communications*, **2020**, 525, 928-935	3.4	8
175	The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease. *Journal of Parkinson's Disease*, **2020**, 10, 523-542	5.3	23
174	The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD. *Brain and Behavior*, **2020**, 10, e01505	3.4	21
173	A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca homeostasis in 3xTg-AD mice. *Neuropharmacology*, **2020**, 170, 108042	5.5	7
172	Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases. *International Review of Neurobiology*, **2020**, 155, 65-89	4.4	5
171	Magnolol alleviates Alzheimer's disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ. *Biomedicine and Pharmacotherapy*, **2020**, 124, 109886	7.5	26
170	GIP has neuroprotective effects in Alzheimer and Parkinson's disease models. *Peptides*, **2020**, 125, 170184	3.8	22
169	A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. *Hormones and Behavior*, **2020**, 118, 104640	3.7	7
168	The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease. *American Journal of Alzheimer's Disease and Other Dementias*, **2020**, 35, 1533317520953041	2.5	11
167	Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease. *Neuropharmacology*, **2020**, 162, 107813	5.5	15
166	D-Ser2-oxyntomodulin ameliorated Aβ1-35-induced circadian rhythm disorder in mice. *CNS Neuroscience and Therapeutics*, **2020**, 26, 343-354	6.8	5
165	The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. *Neuropharmacology*, **2019**, 158, 107748	5.5	29
164	The novel GLP-1/GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model. *Epilepsy Research*, **2019**, 154, 97-106	3	10
163	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). *Trials*, **2019**, 20, 191	2.8	57

162	Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease. *Frontiers in Aging Neuroscience*, **2019**, 11, 88	5.3	41
161	Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. *Journal of Parkinson's Disease*, **2019**, 9, 157-171	5.3	45
160	DA-JC1 improves learning and memory by antagonizing Aβ1-35-induced circadian rhythm disorder. *Molecular Brain*, **2019**, 12, 14	4.5	4
159	Motor Information is Integrated with Spatial Sensory Information in the Hippocampus **2019**, 400-400		
158	Rats are Able to Navigate Successfully in Virtual Reality Environments **2019**, 399-399		
157	Moving towards a more realistic concept of what constitutes Alzheimer's disease. *EBioMedicine*, **2019**, 39, 17-18	8.8	6
156	Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology. *Neuropharmacology*, **2019**, 144, 377-387	5.5	28
155	Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. *Neuropharmacology*, **2018**, 133, 385-394	5.5	50
154	A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease. *Hippocampus*, **2018**, 28, 358-372	3.5	39
153	GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes. *Peptides*, **2018**, 100, 101-107	3.8	30
152	Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. *Neuropharmacology*, **2018**, 136, 251-259	5.5	86
151	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. *Journal of Pathology*, **2018**, 245, 85-100	9.4	127
150	Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus. *Epilepsy Research*, **2018**, 142, 45-52	3	27
149	DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease. *European Journal of Pharmacology*, **2018**, 827, 215-226	5.3	35
148	Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease. *Brain Research*, **2018**, 1678, 64-74	3.7	65
147	Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. *Neuropeptides*, **2018**, 71, 70-80	3.3	48
146	P3-076: QUANTITATIVE METABOLOMICS PROFILING OF BRAIN TISSUE FROM PEOPLE WHO SUFFERED FROM MILD AND SEVERE AD REVEALS DISTINCT BIOCHEMICAL DIFFERENCES WHEN COMPARED TO TISSUE HARVESTED FROM NON-COGNITIVELY IMPAIRED PEOPLE **2018**, 14, P1093-P1094		
145	Evidence That Parietal Lobe Fatty Acids May Be More Profoundly Affected in Moderate Alzheimer's Disease (AD) Pathology Than in Severe AD Pathology. *Metabolites*, **2018**, 8,	5.6	10

144	The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1E9 Mouse Model. *Journal of Alzheimer's Disease*, **2018**, 66, 195-218	4.3	17
143	Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis. *ACS Applied Materials & Interfaces*, **2018**, 10, 36693-36702	9.5	11
142	P4-053: DUAL INCRETIN AGONIST REDUCES NEUROINFLAMMATION IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE **2018**, 14, P1453-P1453		1
141	P3-067: POLY(LACTIC ACID) (PLA) ELECTROSPUN FIBERS IMPROVE NEUROGENESIS AND REDUCE AMYLOID PLAQUES IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE **2018**, 14, P1090-P1090		
140	Therapeutic potential of flavonoids in spinal cord injury. *Reviews in the Neurosciences*, **2017**, 28, 87-101	4.7	6
139	A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease. *Neuropharmacology*, **2017**, 117, 238-248	5.5	46
138	D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation. *European Journal of Pharmacology*, **2017**, 797, 162-172	5.3	32
137	Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease. *CNS Drugs*, **2017**, 31, 639-652	6.7	41
136	A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. *Behavioural Brain Research*, **2017**, 327, 65-74	3.4	65
135	Integrating microRNA and messenger RNA expression profiles in a rat model of deep vein thrombosis. *International Journal of Molecular Medicine*, **2017**, 40, 1019-1028	4.4	16
134	[P3063]: NOVEL BIODEVICE RELEASES DRUG IN VIVO FOR 14 DAYS AND AVOIDS DNA DAMAGE IN STRESS-INDUCED NEUROBLASTOMA CELLS: A PROMISE FOR ALZHEIMER'S DISEASE TREATMENT **2017**, 13, P955-P956		1
133	A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease. *European Journal of Pharmacology*, **2017**, 812, 82-90	5.3	51
132	Levo-tetrahydropalmatine inhibits the acquisition of ketamine-induced conditioned place preference by regulating the expression of ERK and CREB phosphorylation in rats. *Behavioural Brain Research*, **2017**, 317, 367-373	3.4	17
131	A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease. *Molecular Neurobiology*, **2017**, 54, 6827-6838	6.2	7
130	Lixisenatide attenuates the detrimental effects of amyloid protein on spatial working memory and hippocampal neurons in rats. *Behavioural Brain Research*, **2017**, 318, 28-35	3.4	26
129	Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells. *Scientific Reports*, **2017**, 7, 16158	4.9	31
128	Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. *Metabolites*, **2017**, 7,	5.6	67
127	Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease. *Reviews in the Neurosciences*, **2016**, 27, 61-70	4.7	36

126	Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. *Journal of Neurochemistry*, **2016**, 139, 55-67	6	44
125	Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease. *Cardiovascular Endocrinology*, **2016**, 5, 93-98		22
124	Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. *Reviews in the Neurosciences*, **2016**, 27, 689-711	4.7	18
123	A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. *NeuroReport*, **2016**, 27, 384-91	1.7	45
122	Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. *Neurobiology of Aging*, **2016**, 38, 151-163	5.6	70
121	Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model. *Neuropharmacology*, **2016**, 101, 255-63	5.5	48
120	Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. *Brain*, **2016**, 139, 891-907	11.2	265
119	A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. *Brain Research*, **2016**, 1634, 1-11	3.7	61
118	Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer's disease as detected by GC-MS. *American Journal of Translational Research (discontinued)*, **2016**, 8, 154-65	3	22
117	Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease. *Neural Regeneration Research*, **2016**, 11, 326-31	4.5	11
116	A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. *NeuroReport*, **2016**, 27, 23-32	1.7	35
115	Therapeutic Potential of Genipin in Central Neurodegenerative Diseases. *CNS Drugs*, **2016**, 30, 889-97	6.7	17
114	Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model. *Behavioural Brain Research*, **2015**, 293, 107-13	3.4	33
113	Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. *Behavioural Brain Research*, **2015**, 293, 96-106	3.4	71
112	Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. *Neuroscience*, **2015**, 303, 42-50	3.9	118
111	Neuroprotective effects of geniposide on Alzheimer's disease pathology. *Reviews in the Neurosciences*, **2015**, 26, 371-83	4.7	34
110	Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. *European Journal of Pharmacology*, **2015**, 765, 284-90	5.3	24
109	Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease. *European Journal of Pharmacology*, **2015**, 768, 21-7	5.3	70

108	Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide. *Microcirculation*, **2015**, 22, 133-45	2.9	31
107	Quantitative measurement of [Na+] and [K+] in postmortem human brain tissue indicates disturbances in subjects with Alzheimer's disease and dementia with Lewy bodies. *Journal of Alzheimer's Disease*, **2015**, 44, 851-7	4.3	11
106	P4-317: Liraglutide protects the brains of macaques against synapse loss caused by abeta oligomers **2015**, 11, P905-P906		
105	Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. *PLoS ONE*, **2015**, 10, e0119452	3.7	105
104	Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. *Journal of Neurochemistry*, **2014**, 128, 459-71	6	104
103	Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. *Journal of Endocrinology*, **2014**, 221, T31-41	4.7	191
102	Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. *Neuropharmacology*, **2014**, 86, 241-58	5.5	99
101	Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. *Neuropharmacology*, **2014**, 86, 22-30	5.5	54
100	Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. *Biochemical Society Transactions*, **2014**, 42, 593-9	5.1	69
99	Age-associated changes of brain copper, iron, and zinc in Alzheimer's disease and dementia with Lewy bodies. *Journal of Alzheimer's Disease*, **2014**, 42, 1407-13	4.3	44
98	Metabolic signatures of human Alzheimer's disease (AD): 1H NMR analysis of the polar metabolome of post-mortem brain tissue. *Metabolomics*, **2014**, 10, 744-753	4.7	46
97	First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. *Alzheimer's and Dementia*, **2014**, 10, S33-7	1.2	49
96	Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression. *Behavioural Brain Research*, **2014**, 272, 196-204	3.4	43
95	Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. *Neuropharmacology*, **2014**, 76 Pt A, 57-67	5.5	216
94	The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. *Alzheimer's and Dementia*, **2014**, 10, S47-54	1.2	86
93	Neural circuit interactions between the dorsal raphe nucleus and the lateral hypothalamus: an experimental and computational study. *PLoS ONE*, **2014**, 9, e88003	3.7	25
92	New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases. *Neural Regeneration Research*, **2014**, 9, 1870-3	4.5	20
91	Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases. *Acta Physiologica Sinica*, **2014**, 66, 497-510	1.3	20

90	Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. *Alzheimer's Research and Therapy*, **2013**, 5, 20	9	49
89	1H NMR metabolomics investigation of an Alzheimer's disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma. *Metabolomics*, **2013**, 9, 974-983	4.7	33
88	The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. *NeuroMolecular Medicine*, **2013**, 15, 102-14	4.6	103
87	Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. *CNS Drugs*, **2013**, 27, 505-14	6.7	329
86	TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β amyloid oligomers in mice and monkeys. *Cell Metabolism*, **2013**, 18, 831-43	24.6	258
85	Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats. *Neurobiology of Aging*, **2013**, 34, 576-88	5.6	96
84	Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. *Analytical Chemistry*, **2013**, 85, 1803-11	7.8	99
83	The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. *European Journal of Pharmacology*, **2013**, 700, 42-50	5.3	73
82	New animal models of Alzheimer's disease that display insulin desensitization in the brain. *Reviews in the Neurosciences*, **2013**, 24, 607-15	4.7	26
81	Val8GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats. *Journal of Neuroscience Research*, **2013**, 91, 568-77	4.4	19
80	Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. *International Journal of Obesity*, **2013**, 37, 678-84	5.5	57
79	D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model. *Journal of Alzheimer's Disease*, **2013**, 35, 267-83	4.3	45
78	A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1E9 mouse model of Alzheimer's disease. *PLoS ONE*, **2013**, 8, e54769	3.7	65
77	Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. *PLoS ONE*, **2013**, 8, e58784	3.7	75
76	(Val8)glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. *European Journal of Pharmacology*, **2012**, 674, 280-6	5.3	62
75	Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. *European Journal of Pharmacology*, **2012**, 674, 294-306	5.3	47
74	The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease. *Brain Research*, **2012**, 1449, 83-93	3.7	97
73	Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. *Neurobiology of Aging*, **2012**, 33, 265-76	5.6	130

72	Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice. *Peptides*, **2012**, 35, 1-8	3.8	36
71	Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. *BMC Neuroscience*, **2012**, 13, 33	3.2	297
70	Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. *Brain Research*, **2012**, 1473, 204-13	3.7	24
69	Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. *CNS Drugs*, **2012**, 26, 871-82	6.7	122
68	Roles of Glucagon-Like Peptide and Glucose-Dependent Insolinotropic Polypeptide Hormones in Brain Function and Neurodegeneration **2012**, 351-373		
67	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated A□bligomers. *Journal of Clinical Investigation*, **2012**, 122, 1339-53	15.9	567
66	GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. *Reviews in the Neurosciences*, **2011**, 23, 1-11	4.7	114
65	Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. *Biochemical Society Transactions*, **2011**, 39, 891-7	5.1	116
64	The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. *Journal of Neuroscience*, **2011**, 31, 6587-94	6.6	460
63	Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. *Journal of Neurophysiology*, **2011**, 105, 1574-80	3.2	77
62	Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. *European Journal of Pharmacology*, **2011**, 650, 688-93	5.3	57
61	Hepcidin treatment modulates the expression of divalent metal transporter-1, ceruloplasmin, and ferroportin-1 in the rat cerebral cortex and hippocampus. *Biological Trace Element Research*, **2011**, 143, 1581-93	4.5	35
60	Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. *Journal of Neuroscience Research*, **2011**, 89, 481-9	4.4	150
59	Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. *International Journal of Obesity*, **2010**, 34, 1341-4	5.5	74
58	Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. *Diabetes, Obesity and Metabolism*, **2010**, 12, 891-9	6.7	116
57	Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. *PLoS ONE*, **2010**, 5, e9764	3.7	103
56	Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. *Recent Patents on CNS Drug Discovery*, **2010**, 5, 109-17		80
55	New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?. *Neurobiology of Aging*, **2010**, 31, 1495-502	5.6	70

54	The role of GLP-1 in neuronal activity and neurodegeneration. *Vitamins and Hormones*, **2010**, 84, 331-54	2.5	47
53	Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. *European Journal of Pharmacology*, **2010**, 630, 158-62	5.3	130
52	Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. *Brain Research*, **2009**, 1249, 237-43	3.7	22
51	Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. *Behavioural Brain Research*, **2009**, 205, 265-71	3.4	195
50	Quantitative analysis of iron concentration and expression of ferroportin 1 in the cortex and hippocampus of rats induced by cerebral ischemia. *Journal of Clinical Neuroscience*, **2009**, 16, 1466-72	2.2	16
49	Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. *NeuroReport*, **2009**, 20, 1161-6	1.7	180
48	Anaesthesia generates neuronal insulin resistance by inducing hypothermia. *BMC Neuroscience*, **2008**, 9, 100	3.2	15
47	GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. *European Journal of Pharmacology*, **2008**, 587, 112-7	5.3	116
46	Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. *Journal of Neurophysiology*, **2008**, 99, 1590-5	3.2	69
45	Common pathological processes in Alzheimer disease and type 2 diabetes: a review. *Brain Research Reviews*, **2007**, 56, 384-402		277
44	Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. *Experimental Brain Research*, **2007**, 179, 621-30	2.3	35
43	Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. *European Journal of Pharmacology*, **2007**, 561, 85-90	5.3	61
42	Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. *EMBO Reports*, **2006**, 7, 940-6	6.5	626
41	Inactivation of the rat dorsal striatum impairs performance in spatial tasks and alters hippocampal theta in the freely moving rat. *Behavioural Brain Research*, **2005**, 164, 73-82	3.4	34
40	Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. *Reviews in the Neurosciences*, **2005**, 16, 181-212	4.7	68
39	Lack of the metabotropic glutamate receptor subtype 7 selectively modulates Theta rhythm and working memory. *Learning and Memory*, **2005**, 12, 450-5	2.8	37
38	Learned association of allocentric and egocentric information in the hippocampus. *Experimental Brain Research*, **2004**, 158, 233-40	2.3	12
37	Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory. *Behavioural Brain Research*, **2004**, 154, 473-81	3.4	71

36	Perirhinal cortex neuronal activity related to long-term familiarity memory in the macaque. *European Journal of Neuroscience*, **2003**, 18, 2037-46	3.5	57
35	Reward modulates neuronal activity in the hippocampus of the rat. *Behavioural Brain Research*, **2003**, 142, 181-91	3.4	68
34	Time, space and hippocampal functions. *Reviews in the Neurosciences*, **2003**, 14, 253-84	4.7	68
33	Perirhinal cortex neuronal activity is actively related to working memory in the macaque. *Neural Plasticity*, **2002**, 9, 41-51	3.3	24
32	Different strains of rats show different sensitivity to block of long-term potentiation by nitric oxide synthase inhibitors. *European Journal of Pharmacology*, **2002**, 457, 99-106	5.3	21
31	Metabotropic glutamate receptors control gating of spike transmission in the hippocampus area CA1. *Pharmacology Biochemistry and Behavior*, **2002**, 73, 307-16	3.9	6
30	Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. *Journal of Neurophysiology*, **2001**, 85, 708-13	3.2	132
29	Introduction: Long-Term Potentiation as a Model for Memory Mechanisms: The Story So Far **2000**, 1-34		
28	Conclusions and Future Targets **2000**, 476-490		
27	Theta-Facilitated Induction of Long-Term Potentiation: A Better Model for Memory Formation? **2000**, 146-166		
26	Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity. *Neuroscience and Biobehavioral Reviews*, **1999**, 23, 399-410	9	56
25	Nitric oxide is required for expression of LTP that is induced by stimulation phase-locked with theta rhythm. *European Journal of Neuroscience*, **1999**, 11, 335-43	3.5	13
24	Synaptic plasticity and learning and memory: LTP and beyond. *Journal of Neuroscience Research*, **1999**, 58, 62-75	4.4	91
23	Consciousness in mind: a correlate for ACh?. *Trends in Neurosciences*, **1999**, 22, 541-3	13.3	4
22	Stress impairs performance in spatial water maze learning tasks. *Behavioural Brain Research*, **1999**, 100, 225-35	3.4	170
21	Synaptic plasticity and learning and memory: LTP and beyond **1999**, 58, 62		2
20	Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. *Neurobiology of Disease*, **1998**, 5, 129-41	7.5	90
19	Beta-amyloid induced reduction in synaptic transmission is reversed by inhibitors of nitric oxide synthase. *NeuroReport*, **1998**, 9, 1245-8	1.7	12

18	Block of HFS-induced LTP in the dentate gyrus by 1S,3S-ACPD: further evidence against LTP as a model for learning. *NeuroReport*, **1997**, 8, 451-4	1.7	10
17	Activation of group-II metabotropic glutamate receptors blocks induction of long-term potentiation and depotentiation in area CA1 of the rat in vivo. *European Journal of Pharmacology*, **1997**, 322, 155-63	5.3	29
16	Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. *Trends in Neurosciences*, **1997**, 20, 298-303	13.3	342
15	Long-term potentiation: a good model for learning and memory?. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1997**, 21, 47-68	5.5	32
14	Stimulation on the positive phase of hippocampal theta rhythm induces long-term potentiation that can Be depotentiated by stimulation on the negative phase in area CA1 in vivo. *Journal of Neuroscience*, **1997**, 17, 6470-7	6.6	343
13	L-AP4 (L-(+)-2-amino-4-phosphonobutyric acid) induced impairment of spatial learning in the rat is antagonized by MAP4 ((S)-2-amino-2-methyl-4-phosphonobutanoic acid). *Behavioural Brain Research*, **1996**, 81, 69-79	3.4	28
12	Inhibitors of cyclooxygenases produce amnesia for a passive avoidance task in the chick. *European Journal of Neuroscience*, **1995**, 7, 1360-5	3.5	41
11	Prostaglandins play a role in memory consolidation in the chick. *European Journal of Pharmacology*, **1995**, 294, 253-9	5.3	17
10	Inhibitors of PLA2 and NO synthase cooperate in producing amnesia of a spatial task. *NeuroReport*, **1995**, 6, 730-2	1.7	28
9	Quinolinic acid lesion of the rat entorhinal cortex pars medialis produces selective amnesia in allocentric working memory (WM), but not in egocentric WM. *Behavioural Brain Research*, **1994**, 63, 187-94	3.4	52
8	Inhibitors of phospholipase A2 produce amnesia for a passive avoidance task in the chick. *Behavioral and Neural Biology*, **1994**, 61, 225-32		37
7	Inhibitors of metabotropic glutamate receptors produce amnestic effects in chicks. *NeuroReport*, **1994**, 5, 1037-40	1.7	24
6	An inhibitor of nitric oxide synthesis prevents memory formation in the chick. *Neuroscience Letters*, **1992**, 145, 165-7	3.3	141
5	How could populations of neurons encode information?3-18		
4	Theta rhythm and bidirectional plasticity in the hippocampus174-191		
3	Distributed population codes in sensory and memory representations of the neocortex192-223		
2	Functional roles of theta and gamma oscillations in the association and dissociation of neuronal networks in primates and rodents151-173		
1	Summary of chapters, conclusion, and future targets433-469		